Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Brain Scientific Inc. (BRSF)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
6700 Professional Parkway 34240
Sarasota, FL, US
Sarasota, FL, US
CEO
Hassan Kotob
Website
brainscientific.com
IPO
2021-01-08
CIK 1662382 ISIN US10488W2089
Description
Brain Scientific Inc., a medical technology enterprise established in 2013 and based in Sarasota, Florida, delivers neurology-focused medical devices and electric motors across the United States. The company further engages in the development of sophisticated motor platforms, an exceptionally precise micro-dosing pump, and various motion control products. Among its key offerings is NeuroCap, an inventive disposable, soft-layered cap featuring an integrated electrode circuit, specifically engineered to overcome the common challenges of conventional EEG systems. Brain Scientific also provides NeuroEEG, a clinical-grade device available by prescription, designed for capturing, recording, transmitting, and visualizing electrical brain activity in individuals of all ages. Supporting these devices is NeuroNet Cloud, a dedicated database for securely storing and analyzing brain-related data.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26
Beta
1.59
Float Shares
878.0K
Free Float %
70.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | +500.00% | +100.00% | +500.00% | +500.00% | -99.92% | -99.94% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-6.81
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-19.3% Q4'22: -98.0% (vs Q4'21)
-
EPS growth Medical - Devices: +28.5%+48.6% ★ Q4'22: -1,666.7% (vs Q4'21)
-
FCF margin FCF growth · Medical - Devices: +30.9%-5,338.3% Q4'22: -24,590.6% (vs Q4'21)
-
EBIT margin Medical - Devices: +6.2%-4,072.7% Q4'22: -6,401.5% (vs Q4'21)
-
ROIC Medical - Devices: +3.3%-135.8% Q4'22: -20.2% (vs Q4'21)
-
Share dilution Medical - Devices: 0.0%+164.1% Q4'22: -95.9% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.36× Q4'22: -6.94× (vs Q4'21)
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.00M
OE per share TTM
-7.10
Owner's Yield
-804,288.75%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
55.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Goldstein | 8.61M | 41.19% | 1.52M | 7.09M | 1.52M | 7.09M | IN | U.S. | 2021-02-16 | ↗ |
| 2 | Technology Capital Fund LP | 6.75M | 34.26% | — | 6.75M | — | 6.75M | PN | U.S. | 2021-02-16 | ↗ |
| 3 | Andrew M. Brown | 2.60M | 5.08% | 2.60M | — | 2.60M | — | IN | Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 4 | Thomas Caleca | 2.40M | 4.70% | 2.40M | — | 2.40M | — | IN | Citizenship or Place of Organization | 2022-02-14 | ↗ |
| 5 | s: Andrew M. Brown | 1.79M | 9.02% | 1.79M | — | 1.79M | — | IN | USA | 2021-02-23 | ↗ |
| 6 | Kukekov | 1.50M | 7.58% | 116.8K | 1.38M | 116.8K | 1.38M | IN | U.S. | 2021-02-16 | ↗ |
| 7 | Lifestyle Healthcare LLC | 1.38M | 7.03% | — | 1.38M | — | 1.38M | OO | U.S. | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
25.49M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+25,485,426
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-19 | Olivier Thomas | Director | A-Award | A | Options to purchase Common Stock | 304,608 | 0.00 | — | 304,608 | — | ↗ |
| 2022-08-19 | MacKenzie Donald S | Director | A-Award | A | Options to purchase Common Stock | 304,608 | 0.00 | — | 304,608 | — | ↗ |
| 2022-08-19 | Kukekov Nickolay V. | Director | A-Award | A | Options to purchase Common Stock | 304,608 | 0.00 | — | 304,608 | — | ↗ |
| 2022-08-19 | Kotob Hassan | Director / Officer | A-Award | A | Stock Option (right to buy) | 22,930,987 | 0.00 | — | 22,930,987 | — | ↗ |
| 2022-08-19 | Gerety Bonnie-Jeanne | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,293,150 | 0.00 | — | 1,293,150 | — | ↗ |
| 2022-08-19 | Cloutier Daniel Danny | Director | A-Award | A | Options to purchase Common Stock | 304,608 | 0.12 | 36.6K | 304,608 | — | ↗ |
| 2022-08-19 | Anthony Farid | Officer | A-Award | A | Options to Purchase Shares of Common Stock | 42,857 | 0.12 | 5.1K | 42,857 | — | ↗ |
| 2022-06-15 | MANCHESTER MANAGEMENT CO LLC | 10% Owner | — | I | Common Stock Purchase Warrant | 4,784,294 | 0.25 | 1.20M | 0 | — | ↗ |
| 2022-05-19 | Kotob Hassan | Director / Officer | A-Award | A | Stock Option (right to buy) | 780,000 | 0.00 | — | 780,000 | — | ↗ |
| 2022-05-19 | Gerety Bonnie-Jeanne | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-02-03 | Olivier Thomas | Director | A-Award | A | Options to Purchase Shares of Common Stock | 362,069 | 0.29 | 105.0K | 362,069 | — | ↗ |
| 2022-02-03 | MacKenzie Donald S | Director | A-Award | A | Options to Purchase Shares of Common Stock | 362,069 | 0.00 | — | 362,069 | — | ↗ |
| 2022-02-03 | Cloutier Daniel Danny | Director | A-Award | A | Options to Purchase Common Stock | 362,069 | 0.29 | 105.0K | 362,069 | — | ↗ |
| 2021-12-30 | Anthony Farid | Officer | A-Award | A | Options to Purchase Shares of Common Stock | 476,190 | 0.21 | 100.0K | 476,190 | — | ↗ |
| 2021-12-10 | Kotob Hassan | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,218,248 | 0.21 | 255.8K | 1,218,248 | — | ↗ |
| 2021-12-10 | Gerety Bonnie-Jeanne | Officer | A-Award | A | Stock Option (right to buy) | 476,190 | 0.21 | 100.0K | 476,190 | — | ↗ |
| 2021-11-10 | MacKenzie Donald S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-08 | Olivier Thomas | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-08 | Cloutier Daniel Danny | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-08 | Anthony Farid | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-21 | kotob Hassan | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,218,248 | 0.39 | 475.1K | 1,218,248 | — | ↗ |
| 2021-10-02 | MANCHESTER MANAGEMENT CO LLC | 10% Owner | — | D | Common Stock Purchase Warrant | 1,251,171 | 0.35 | 437.9K | 0 | — | ↗ |
| 2021-10-01 | kotob Hassan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-01 | Kukekov Nickolay V. | Director | A-Award | A | Options to Purchase Shares of Common Stock | 2,001,873 | 0.35 | 700.7K | 2,001,873 | — | ↗ |
| 2021-10-01 | Gerety Bonnie-Jeanne | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-26 | Kukekov Nickolay V. | Director | A-Award | A | Stock Option (Right to Buy) | 16,779 | 1.49 | 25.0K | 16,779 | — | ↗ |
| 2020-10-15 | Kukekov Nickolay V. | Director | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,384,980 | — | ↗ |
| 2020-10-15 | Goldstein Boris | Director / Officer / 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 6,749,000 | — | ↗ |
| 2020-10-15 | Corrao Mark | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-09-01 | Kukekov Nickolay V. | Director | — | D | Common Stock Purchase Warrant | 100,000 | 0.40 | 40.0K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.9K
Shares Outstanding
1.24M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2021-06-16 | DEFA14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hassan Kotob | Chief Executive Officer & Chairman | 693.1K | male |
| Mark Broderick | President of Piezo Motion Corporation | 250.0K | — |
| Daniel Cloutier | Chief Revenue Officer & Director | — | male |
| Kevin Winterfield | Vice President of Marketing & Communications | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BRSF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
